Vecuronium Bromide for Injection Rx
Generic Name and Formulations:
Vecuronium bromide 10mg/10mL; pwd for IV inj after reconstitution; contains benzyl alcohol, mannitol.
Various generic manufacturers
Indications for Vecuronium Bromide for Injection:
Adjunct to general anesthesia to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Adults and Children:
<7wks: not recommended. Individualize. >7wks–10yrs: see literature. ≥10yrs: Relaxation for intubation: inject bolus dose of 0.08–0.1mg/kg; may reduce dose to 0.06–0.085mg/kg if given >5 minutes after start of inhalation agent or when steady state has been achieved. Give 1microgram/kg/min (range: 0.8–1.2microgram/kg/min) by continuous IV infusion 20–40 minutes after initial dose. Inhalation anesthetics (eg, enflurane, isoflurane): reduce infusion rate 25–60%, 45–60 minutes after initial dose. Intubation with succinylcholine: reduce initial vecuronium dose to 0.04–0.06mg/kg with inhalation anesthesia; and to 0.05–0.06mg/kg with balanced anesthesia. Prolonged surgery: maintenance dose of 0.01–0.015mg/kg, within 25–40 minutes of initial dose. During surgery under halothane anesthesia: initial dosing range from 0.15mg/kg up to 0.28mg/kg have been given. Monitor with a peripheral nerve stimulator to avoid overdosage.
To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Myasthenia gravis or myasthenic (Eaton-Lambert) syndrome (do test dose and monitor). Renal failure. Hepatic impairment. Cardiovascular disease and edematous state. Long-term use in I.C.U. Immobilized for long periods. Severe obesity or neuromuscular disease; monitor airway and ventilation. Electrolyte imbalance. Adrenal cortical insufficiency. Malignant hyperthermia. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Neuromuscular blocker (nondepolarizing).
Prior administration of succinylcholine may potentiate effects (delay vecuronium dose). Potentiated by volatile inhalational anesthetics (eg, enflurane, isoflurane, halothane), aminoglycosides, tetracyclines, bacitracin, polymyxin B, colistin, sodium colistimethate, magnesium salts. Additive effects with pancuronium, d-tubocurarine, metocurine, and gallamine. Caution with quinidine injection.
Skeletal muscle weakness or prolonged paralysis, muscle atrophy, respiration insufficiency, apnea; rare: hypersensitivity reactions.
Formerly known under the brand name Norcuron.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Romosozumab: Effective in Men With Osteoporosis
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Testosterone Prescribing Trends in the United States Between 2002 and 2016
- The Future of Food and Drug Regulation: Trump Administration Proposes Reorganization of FDA, USDA
- Popliteal Sciatic Nerve Block May Increase Time to First Opioid Request in Diabetic Peripheral Neuropathy
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Subclinical Hypothyroidism: Controversies in Testing and Treatment